Glabellar Lines: Clinical Trials

52 trials for Glabellar Lines, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed, 4 recruiting, 2 not yet recruiting, 2 unknown. 28 Phase 3, 8 Phase 1, 8 Phase 2, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 328Completed 22, Not yet recruiting 2, Recruiting 2, Unknown 2
Phase 18Completed 7, Recruiting 1
Phase 28Completed 6, Active not recruiting 1, Recruiting 1
Phase 43Completed 3

Follow Glabellar Lines: new trials by email Literature Review of Glabellar Lines trials Research Report on Glabellar Lines

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of DWP450 in Japanese Subjects With Glabellar Lines
DWP450 20 U, 0.9% Saline Solution 0.5 mL - Glabellar Lines		Phase 3Not yet recruitingDaewoong Pharmaceutical Co. LTD.1202027-01-012026-08-26
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines		Phase 2RecruitingAbbVie3002026-10-072026-10-13
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
HU-045, Xeomin® - Glabellar Lines		Phase 3RecruitingHuons Biopharma3902026-09-032026-10-13
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
AGN-151586, BOTOX - Glabellar Lines		Phase 1RecruitingAbbVie1202026-08-102026-09-09
A Study to Evaluate AI-09 In Participants With Glabellar Lines
AI-09 Ready Use Injectable Botulinum Toxin, Vehicle - Glabellar Lines		Phase 2Active not recruitingEirion Therapeutics Inc.682025-12-032026-01-07
Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
Letybo®, Philart® Eye, Saypha® Volume Plus Lidocaine - Glabellar Lines, Midface Volume Deficiency		CompletedYuvell292025-09-022026-03-23
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
DWP712 inj., Botox® 100 Units - Glabellar Lines		Phase 3Not yet recruitingDaewoong Pharmaceutical Co. LTD.3242025-07-152025-06-10
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
AGN-151586, OnabotulinumtoxinA, Placebo - Glabellar Lines		Phase 1CompletedAbbVie1322025-02-182025-11-17
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
JTM201, Placebo - Glabellar Lines		Phase 2CompletedJetema USA Inc.4802024-10-262025-08-29
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
HU-045, Xeomin® - Glabellar Lines		Phase 3RecruitingHuons Biopharma3122024-06-202024-10-03
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.) - Glabellar Lines, Glabellar Frown Lines		Phase 3CompletedEspad Pharmed1462024-05-282025-05-07
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
AGN-151586, Placebo - Glabellar Lines		Phase 3CompletedAbbVie1612024-03-292026-06-26
A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A
Letybo® - Glabellar Lines, Forehead Lines		CompletedYuvell202024-01-292026-01-29
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
Botulinum Toxin Type A Injection [HG102], Botulinum Toxin Type A Injection [Botox] - Glabellar Lines		Phase 3UnknownHugel2722024-01-042024-01-16
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
DWP712, BOTOX® - Glabellar Lines		Phase 1CompletedDaewoong Pharmaceutical Co. LTD.202023-11-282024-04-04
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
CKDB-501A, Botox® - Glabellar Lines		Phase 3CompletedCKD Bio Corporation3002023-04-132023-12-12
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
AGN-151586, BOTOX, Placebo - Glabellar Lines		Phase 1CompletedAbbVie902022-08-302026-06-26
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
CKDB-501B, Botox®50U - Glabellar Lines		Phase 1CompletedCKD Bio Corporation302022-06-222022-11-17
Phase 2 of HU-045 in Glabellar Lines
HU-045, Xeomin® - Glabellar Lines		Phase 2CompletedHuons Co., Ltd.502022-03-282023-07-05
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Placebo, AGN-151586 - Glabellar Lines		Phase 3CompletedAbbVie6382022-03-162024-05-24

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Hyperhidrosis (1)  ·  Muscle Spasticity (1)

Broader conditions

Muscle Hypertonia (1)  ·  Muscular Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Nervous System Diseases (1)  ·  Neurologic Manifestations (1)  ·  Neuromuscular Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)  ·  Sweat Gland Diseases (1)

Interventions

Botulinum Toxins, Type A (28)  ·  incobotulinumtoxinA (7)  ·  Saline Solution (3)  ·  abobotulinumtoxinA (3)  ·  Injections (2)  ·  Bimatoprost (1)  ·  DWP450 (1)  ·  Sodium Chloride (1)

Sponsors

Allergan (10)  ·  AbbVie (8)  ·  Medy-Tox (5)  ·  Daewoong Pharmaceutical Co. LTD. (4)  ·  CKD Bio Corporation (3)  ·  Galderma R&D (3)  ·  Hugel (3)  ·  Ipsen (3)  ·  Huons Biopharma (2)  ·  Huons Co., Ltd. (2)  ·  Yuvell (2)  ·  BMI Korea (1)  ·  Eirion Therapeutics Inc. (1)  ·  Espad Pharmed (1)  ·  GlaxoSmithKline (1)

Countries

United States (23)  ·  South Korea (15)  ·  Canada (9)  ·  Germany (9)  ·  China (4)  ·  France (4)  ·  Russia (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Czechia (1)

Top investigators

SangMi Park (4)  ·  Alireza Firooz, Medical Doctor (1)  ·  Beom Joon Kim, MD, Ph.D (1)  ·  Beom Joon Kim, MD, Ph.D. (1)  ·  Beomjoon Kim (1)  ·  Berthold Rzany, Prof. Dr. med Sc.M. (1)  ·  Jay Mashburn, PhD (1)

Results publications

PMID 23190342, PMID 30120518, PMID 36206385, PMID 40586136

NIH funding

2014 (4), 2018 (1)